Potential new drugs for therapy of chronic obstructive pulmonary disease

Bibliography

• PAUWELS RA, BUIST AS, CALVERLEY PMA, JENKINS C, HURD S: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am. Respic Grit. Care Med. (2001) 163:1256–1276.
   PubMedGoogle Scholar
• ••This is the summary of the GOLD workshop that provides international guidelines for treatment of COPD.
   Google Scholar
• WORLD HEALTH ORGANISATION: World health report 2000. World Health Organisation, Geneva (2000).
   Google Scholar
• RENNARD S, DECRAMER M, CALVERLEY PM et al.: Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur. Respic (2002) 20:799–805.
   PubMed Web of Science ®Google Scholar
• CROXTON TL, WEINMANN GG, SENIOR RM, HOIDAL JR: Future research directions in chronic obstructive pulmonary disease. Am. J. Respic Crit. Care Med. (2002) 165:838–844.
   PubMedGoogle Scholar
• BARNES PJ: New concepts in chronic obstructive pulmonary disease. Ann. Rev Med. (2003) 54:113–129.
   PubMed Web of Science ®Google Scholar
• ••This review comprises several of thehypothesised concepts of the initiation and progression of COPD, and potential therapy with a wide range of new drugs.
   Google Scholar
• BUIST AS: Guidelines for the management of chronic obstructive pulmonary disease. Respir. Med. (2002) 96(Suppl. C):S11–S16.
   Google Scholar
• JANS MP, SCHELLEVIS FG, LE COQ EM, BEZEMER PD, VAN EIJK JT: Health outcomes of asthma and COPD patients: the evaluation of a project to implement guidelines in general practice. Int. .1. Qua]. Health Care (2001) 13:17–25.
   PubMed Web of Science ®Google Scholar
• LAITINEN LA, KOSKELA K: Chronic bronchitis and chronic obstructive pulmonary disease: Finnish National Guidelines for Prevention and Treatment 1998-2007. Respic Med. (1999) 93:297–332.
   PubMed Web of Science ®Google Scholar
• ALSAEEDI A, SIN DD, MCALISTER FA: The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. (2002) 113:59–65.
   PubMed Web of Science ®Google Scholar
• ••An important meta-analysis on ninedifferent trials with inhaled corticosteroids in COPD. It shows the effects of steroid treatment on COPD including an improved incidence of exacerbations and general side effects.
   Google Scholar
• CALVERLEY P, PAUWELS R, VESTBO J et al: Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 361:449–456.
   PubMed Web of Science ®Google Scholar
• BURGE PS, CALVERLEY PM, JONES PW, SPENCER S, ANDERSON JA, MASLEN TK: Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. 1 (2000) 320:1297-1303.
   Google Scholar
• VESTBO J, SORENSEN T, LANGE P, BRIX A, TORRE P, VISKUM K: Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (1999) 353:1819–1823.
   PubMed Web of Science ®Google Scholar
• AGUSTI AGN, NOGUERA A, SAULEDA J, SALA E, PONS J, BUSQUETS X: Systemic effects of chronic obstructive pulmonary disease. Ear: Respir. J. (2003) 21:347–360.
   PubMed Web of Science ®Google Scholar
• •An extensive review on systemic effects of COPD including systemic inflammation, multiorgan effects of tobacco smoke and clinical implications.
   Google Scholar
• JEFFERY PK: Remodeling in asthma and chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. (2001) 164:S28–S38.
   PubMed Web of Science ®Google Scholar
• •One of the several papers by the same author on the pathological and lung morphological aspects of COPD, its subtypes and asthma.
   Google Scholar
• SAKAO S, TATSUMI K, IGARI H et al: Association of tumor necrosis factor a gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am. I Respir. Grit. Care Med. (2001) 163:420–422.
   PubMed Web of Science ®Google Scholar
• KEATINGS VM, CAVE SJ, HENRY MJ et al.: A polymorphism in the tumor necrosis factor-a gene promoter region may predispose to a poor prognosis in COPD. Chest (2000) 118:971–975.
   PubMed Web of Science ®Google Scholar
• HUANG S-L, SU C-H, CHANG S-C: Tumor necrosis factor-a gene polymorphism in chronic bronchitis. Am. J. Respir. Grit. Care Med. (1997) 156:1436–1439.
   PubMed Web of Science ®Google Scholar
• HE JQ, RUAN J, CONNETT JE, ANTHONISEN NR, PARE PD, SANDFORD AJ: Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers. Am. J. Respir. Crit. Care Med. (2002) 136:323–328.
   Web of Science ®Google Scholar
• DI STEFANO A, CAPELLI A, LUSUARDI M et al.: Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am. J. Respir. Grit. Care Med. (1998) 158:1277–1285.
   PubMed Web of Science ®Google Scholar
• SAETTA M, TURATO G, FACCHINI FM et al: Inflammatory cells in the bronchial glands of smokers with chronic bronchitis. Am. I Respir. Crit. Care Med. (1997) 156:1633–1639.
   PubMed Web of Science ®Google Scholar
• GRASHOFF WFH, SONT JK, STERK PJ et al.: Chronic obstructive pulmonary disease: the role of bronchiolar mast cells and macrophages. Am. J. Pathol (1997) 151:1785–1790.
   PubMed Web of Science ®Google Scholar
• SAETTA M, MARIANI M, PANINA-BORDIGNON P et al.: Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. (2002) 165:1404–1409.
   PubMed Web of Science ®Google Scholar
• •The first, descriptive study in COPD that tried to link an increase in numbers of CD8+ T cells in COPD to an augmented expression of the chemotactic chemokine CXCL10.
   Google Scholar
• O'SHAUGHNESSY TC, ANSARI TW,BARNES NC et al.: Inflammation in bronchial biopsies of subjects with chronic bronchitis: inverse relationship of CD8+ T lymphocytes with FEVi. Am. I Respir. Crit. Care Med. (1997) 155:852–857.
   Google Scholar
• FOURNIER M, LEBARGY F, LE ROY LADURIE F, LENORMAND E, PARIENTE R: Intra-epithelial T-lymphocyte subsets in the airways of normal subjects and of patients with chronic bronchitis. Am. Rev Respir. Dis. (1989) 140:737–742.
   PubMed Web of Science ®Google Scholar
• PEINADO VI, BARBERA JA, ABATE Pet al.: Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am. Respir. Crit. Care Med. (1999) 159:1605–1611.
   Google Scholar
• LACOSTE J-Y, BOUSQUET J, CHANEZ P et al.: Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. Allergy Gin. Immunol (1993) 92:537–548.
   PubMed Web of Science ®Google Scholar
• BRIGHTLING CE, MONTEIRO W, WARD R et al.: Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2000) 356:1480–1485.
   PubMed Web of Science ®Google Scholar
• PIZZICHINI E, PIZZICHINI MM, GIBSON P et al.: Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am. J. Respir. Crit. Care Med. (1998) 158:1511–1517.
   PubMed Web of Science ®Google Scholar
• DE BOER WI: Cytokines and therapy inCOPD: a promising combination? Chest (2002) 121 (Suppl.):209S–218S.
   Google Scholar
• •A good overview of cytokine and chemokine expression in COPD and the benefits and pitfalls of cytokine therapy in COPD.
   Google Scholar
• LIM S, ROCHE N, OLIVER BG, MATTOS W, BARNES PJ, CHUNG KF: Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am. J. Respir. Grit. Care Med. (2000) 162:1355–1360.
   PubMed Web of Science ®Google Scholar
• HATTOTUWA KL, GIZYCKI MJ, ANSARI TW, JEFFERY PK, BARNES NC: The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am. I Respir. Grit. Care Med. (2002) 165:1592–1596.
   PubMed Web of Science ®Google Scholar
• HUBBARD RB, SMITH CJP, SMEETH L, HARRISON TW, TATTERSFIELD AE: Inhaled corticosteroids and hip fractures. A population-based case-control study. Am. J. Respir. Crit. Care Med. (2002) 166:1563–1566.
   PubMed Web of Science ®Google Scholar
• GROOTENDORST DC, RABE KF: Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Current Opin. Allergy Clin. Immunol (2002) 2:61–67.
   PubMed Web of Science ®Google Scholar
• MISISCHIA RJ, MORELAND LW: Rheumatoid arthritis: developing pharmacological therapies. Expert Opin. Investig. Drugs (2002) 11:927–935.
   PubMed Web of Science ®Google Scholar
• SANDBORN WJ, TARGAN SR: Biologictherapy of inflammatory bowel disease. Gastroenterology (2002) 122:1592–1608.
   PubMed Web of Science ®Google Scholar
• KEATINGS VM, JATAKANON A, WORSDELL YM et al.: Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am. I Respir. Grit. Care Med. (1996) 155:542–548.
   Web of Science ®Google Scholar
• NGUYEN LT, BEDU M, CAILLAUD D et al.: Increased resting energy expenditure is related to plasma TNF-a concentration in stable COPD patients. Gin. Num. (1999) 18:269–274.
   Google Scholar
• RABINOVICH RA, FIGUERAS M, ARDITE E et al.: Increased TNF-a plasma levels during moderate intensity exercise in COPD patients. Am. J. Respir. Crit. Care Med. (2002) 165(Suppl.):A823.
   Google Scholar
• KOCOKAYCAN M, VAN KRUGTEN M, PENNINGS H-J et al.: Tumor necrosis factor-a +489G/A gene polymorphism is associated with chronic obstructive pulmonary disease. Respir. Res. (2002) 3:29.
   PubMed Web of Science ®Google Scholar
• SAKAO S, TATSUMI K, IGARI H et al.:Association of tumor necrosis factor-a gene promoter polymorphism with low attenuation areas on high-resolution CT in patients with COPD. Chest (2002) 122:416–420.
   PubMed Web of Science ®Google Scholar
• CHURG A, DAI J, TAI H, XIE C, WRIGHT JL: Tumor necrosis factor-a is central to acute cigarette smoke-induced inflammation and connective tissue breakdown. Am. J Respir. Crit. Care Med. (2002) 166:849–854.
   PubMed Web of Science ®Google Scholar
• •This study showed a clear involvement of TNF-a in the tobacco smoke-induced airways inflammation by neutrophils and monocytes and the increased chemokine expression.
   Google Scholar
• GOTTLIEB AB, MASUD S, RAMAMURTHI R et al: Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-a monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris. Am. Acad. Dermatol (2003) 48:68–75.
   PubMed Web of Science ®Google Scholar
• BREBAN M, VIGNON E, CLAUDEPIERRE P et al.: Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. Rheumatology (2002) 41:1280–1285.
   PubMed Web of Science ®Google Scholar
• GORMAN JD, SACK KE, DAVIS JC Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor a. N Engl. J Med. (2002) 346:1349–1356.
   PubMed Web of Science ®Google Scholar
• SCHOPF RE, AUST H, KNOP J: Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor a, infliximab. J. Am. Acad. Dermatol (2002) 46:886–891.
   PubMed Web of Science ®Google Scholar
• HARRIS JM, CHESS RB: Effect of PEGylation on pharmaceuticals. Nat. Rev Drug Discov. (2003) 2:214–221.
   PubMed Web of Science ®Google Scholar
• ROSENBERG JJ, MARTIN SW, SEELY JE et al.: Development of a novel, nonimmunogenic, soluble human TNF receptor Type I (sTNFR-I) construct in the baboon. J Appl. Physiol (2001) 91:2213–2223.
   PubMed Web of Science ®Google Scholar
• ••An extensive study on a variety ofconstructs of TNF-R-I proteins, conjugated to polyethyleenglycol or the Fc part of human IgGl. The study provided, for example, in vitro neutralisation studies and efficacy studies in baboons.
   Google Scholar
• WAGNER TE, HUSEBY ES, HUSEBYJS: Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn's disease after treatment with a tumor necrosis factor-a inhibitor. Am. J Med. (2002) 112:67–69.
   PubMed Web of Science ®Google Scholar
• MOHAN N, EDWARDS E, CUPPS T et al.: Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritis. Arthritic Rheum. (2001) 44:2862–2869.
   PubMed Web of Science ®Google Scholar
• BABU SK, HASAN AS, BELL EJ et al.: Etanercept for the treatment of patients with chronic asthma. Chest (2002) 122(Suppl.):64S.
   Google Scholar
• CATALDO D, MUNAUT C, FRANKENNE F et al.: MMP-2 and MMP-9-linked gelatonolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease. Int. Arch. Allergy Immunol (2000) 123:259–267.
   PubMed Web of Science ®Google Scholar
• CONWAY JG, ANDREWS RC, BEAUDET B et al.: Inhibition of tumor necrosis factor-a (TNFa) production and arthritis in the rat by GW3333, a dual inhibitor of TNFa-converting enzyme and matrix metalloproteinases. Pharmacol Exp. Ther. (2001) 298:900–908.
   PubMed Web of Science ®Google Scholar
• •This study shows a concept for a compound that acts bidirectionally: inhibition of MMPs and reduction of maturation of TNF-a proteins, both of which may be involved in the progression of COPD.
   Google Scholar
• TRIFILIEFF A, WALKER C, KELLER T,KOTTIRSCH G, NEUMANN U: ha vivo pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-a converting enzyme and matrix metalloproteinases, in models of airway inflammation. Ear: Respir. J. (2002) 20 (Suppl. 38):169s.
   Google Scholar
• QUIRT I, BODURTH A, LOHMANN R et al.: Phase II study of marimastat (BB-2516) in malignant melanoma: A clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group. Invest. New Drugs (2002) 20:431–437.
   PubMed Web of Science ®Google Scholar
• MYERS KJ, MURTHY S, FLANIGAN A et al.: Antisense oligonucleotide blockade of tumor necrosis factor-a in two murine models of colitis. Pharmacol Exp. Ther. (2003) 304:411–424.
   PubMed Web of Science ®Google Scholar
• NYCE J: Respirable antisense oligonucleotides: a new, third drug class targeting respiratory disease. Can: Opin. Allergy Clin. Immunol (2002) 2:533–536.
   PubMed Web of Science ®Google Scholar
• TAKANASHI S, HASEGAWA Y, KANEHIRA Y et al.: Interleuldn-10 level in sputum is reduced in bronchial asthma, COPD and in smokers. Ear: Respir. (1999) 14:309–314.
   PubMed Web of Science ®Google Scholar
• KOCABAS A, HANTA I, KULECI S: The role of interleukins in development of chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care Med. (2002) 165(Suppl.):B6.
   Google Scholar
• WOOLLEY T, VVEYMAN-JONES C, LANGLEY S, YOUNG A, SARGENT C: Systemic levels of IL-1Ra and IL-s1RII are modulated in stable COPD patients. Am. J. Respir. Crit. Care Med. (2002) 165(Suppl.):A597.
   Google Scholar
• DIGNETTI P, LEVA M, MINCARINI M, RICCIO A, SCORDAMAGLIA A, CANONICA GW: Cytokine concentrations in induced sputum of mild COPD patients. Correlation to clinical response to inhaled corticosteroids. Ear: Respir (2002) 20\(Suppl. 38):309s.
   Google Scholar
• CASTLE PE, HILDESHEIM A, BOWMAN FP et al.: Cervical concentrations of interleukin-10 and interleukin-12 do not correlate with plasma levels. J. Clin. Immunol (2002) 22:23–27.
   PubMed Web of Science ®Google Scholar
• MOORE KW, DE WAAL MALEFYT R, COFFMAN RL, O'GARRA A: Interleukin-10 and the interleukin-10 receptor. Ann. Rev Immunol (2001) 19:683–765.
   PubMed Web of Science ®Google Scholar
• CUZZOCREA S, MAZZON E, DUGO L et al.: Absence of endogenous interleukin-10 enhances the evolution of acute lung injury. Eur. Cytokine Netw. (2002) 13:285–297.
   PubMed Web of Science ®Google Scholar
• FRIEDRICH M, DOCKE WD, KLEIN A et al.: Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. Invert. Dermatol (2002) 118:672–677.
   PubMed Web of Science ®Google Scholar
• COLOMBEL J-F, RUTGEERS P, MAL CHOW H et al.: Interleuldn 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut (2001) 49:42–46.
   Google Scholar
• REICH K, GARBE C, BLASCHKE V et al.: Response of psoriasis to interleukin- 10 is associated with suppression of cutaneous Type 1 inflammation, downregulation of the epidermal interleukin-8/CXCR2 pathway and normalization of keratinocyte maturation. Invest. Dermatol (2001) 116:319–329.
   PubMed Web of Science ®Google Scholar
• ASADULLAH K, DOCKE WD, SABAT RV, VOLK HD, STERRY W: The treatment of psoriasis with IL-10: rationale and review of the first clinical trials. Expert Opin. Investig. Drugs (2000) 9:95–102.
   PubMed Web of Science ®Google Scholar
• TILG H, ULMER H, KASER A, WEISS G: Role of IL-10 for induction of anemia during inflammation. Immunol (2002) 169:2204–2209.
   Web of Science ®Google Scholar
• FEDORAK RN, GANGL A, ELSON CO et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately Crohn's disease. Gastroenterology (2000) 119:1473–1482.
   PubMed Web of Science ®Google Scholar
• SCHWARZ YA, AMIN RS, STARK JM, TRAPNELL BC, WILMOTT RW: Interleukin-1 receptor antagonist inhibits interleukin-8 expression in A549 respiratory epithelial cells infected M vitro with a replication-deficient recombinant adenovirus vector. Am. I Respir. Cell Mol Biol. (1999) 21:388–394.
   PubMed Web of Science ®Google Scholar
• WILMOTT RW, KITZMILLER JA, FIEDLER MA, STARK JM: Generation of a transgenic mouse with lung-specific overexpression of the human interleukin-1 receptor antagonist protein. Am. Respir. Cell Ma Biol. (1998) 18:429–434.
   PubMed Web of Science ®Google Scholar
• CALKINS CM, BENSARD DD, SHAMES BD et al.: IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia. Endotoxin Res. (2002) 8:59–67.
   PubMedGoogle Scholar
• COHEN SB, WOOLEY JM, CHAN W:Interleukin 1 receptor anakinra improves functional status in patients with rheumatoid arthritis. Rheumatol (2003) 30:225–231.
   Web of Science ®Google Scholar
• COHEN S, HURD E, CUSH Jet al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:614–624.
   Google Scholar
• NUKI G, BRESNIHAN, BEAR MB, MCCABE D: Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomize, double-blind, placebo-controlled trial. Arthritic Rheum. (2002) 46:2838–2846.
   PubMed Web of Science ®Google Scholar
• ECONOMIDES AN, ROCCO CARPENTER L, RUDGE JS et al.: Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. (2003) 9:47–52.
   PubMed Web of Science ®Google Scholar
• GULER H-P: A Phase I, single dose escalation study of IL-1 trap in patients with rheumatoid arthritis. Arthritis Rheum. (2001) 44(59):s370.
   Google Scholar
• PERREGAUX DG, MCNIFF P, LALIBERTE R et al.: Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. Pharmacol Exp. Ther. (2001) 299:187–197.
   PubMed Web of Science ®Google Scholar
• ICHIKAWA K, HIRAI H, ISHIGURO M et al.: Novel cytokine production inhibitors produced by basidiomycete, Marasmiellus sp. J. Antibia (2001) 54:703–709.
   PubMed Web of Science ®Google Scholar
• O'DONNELL R, MORRIS B, WARD J et al.: Augmented expression of epithelial IL-8 and GRO-a occurs in vivo in COPD. Am. j Respir. Grit. Care Med. (2002) 165 (Suppl.):A600.
   Google Scholar
• DE BOER WI, SONT JK, VAN SCHADEWIJK A et al.: Monocyte chemoattractant protein 1, interleukin 8, and chronic obstructive airways inflammation in COPD. J. Pathol (2000) 190:619–626.
   Google Scholar
• TANINO M, BETSUYAKU T, TAKEYABU K et al.: Increased levels of interleukin-8 in BAL fluid from smokers susceptible to pulmonary emphysema. Thorax (2002) 57:405–411.
   PubMed Web of Science ®Google Scholar
• TRAVES SL, CULPITT SV, RUSSELL RE, BARNES PJ, DONNELLY LE: Increased levels of the chemokines GROa and MCP-1 in sputum samples from patients with COPD. Thorax (2002) 57:590–595.
   PubMed Web of Science ®Google Scholar
• CULPITT SV, MAZIAK W, LOUDIKIS S et al.: Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am. I Respir. Crit. Care Med. (1999) 160:1635–1639.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO C, YONEDA T, YOSHIKAWA M et al.: Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest (1997) 112:505–510.
   PubMed Web of Science ®Google Scholar
• QIU Y, ZHU J, BANDI Vet al.: Endobronchial biopsy neutrophilia, IL-8, ENA-78, and neutrophil chemokine receptor (CXCR1 & CXCR2) gene expression in severe exacerbations of COPD. Eur. Respir J. (2002) 20\(Suppl. 38):377s.
   Google Scholar
• AUSTIN CE, WOOLLEY ST, CHRISTIE M et al.: CXCR1 and CXCR2 expression on leukocytes from normal and COPD patients. Am. I Respir. Crit. Care Med. (2002) 165 (Suppl.):A597.
   Google Scholar
• TRAVES SL, SMITH SJ, BARNES PJ, DONNELLY LE: Increased migration of monocytes from COPD patients towards GROa is not mediated by an increase in CXCR2 receptor expression. Am. I Respir. Grit. Care Med. (2002) 165(Suppl.):A824.
   Google Scholar
• HE JQ, PARE PD, ANTHONISEN N, CONNETT J, SANDFORD A: Polymorphisms of the interleukin-8 and CXCR receptor 1 and 2 genes and rate of decline of lung function in smokers. Am. Respir. Crit. Care Med. (2002) 165 (Suppl.):A442.
   Google Scholar
• BELMONTE KE, HARDAKER E, BACON AM, SARAU HM: Regulation of IP-10 expression: participation of airway muscle in the inflammatory response in COPD. Am. I Respir. Grit. Care Med. (2002) 165 (Suppl.):A462.
   Google Scholar
• GACZKOWSKI MP, STURTON G, STAIB P, KOCH A: Decreased numbers of human peripheral blood CD8+ve T-lymphocytes and the modification of their specific surface antigens in COPD. Ear: Respir. (2002) 20\(Suppl. 38):3095.
   Google Scholar
• HUANG S, MILLS L, MIAN B et al: Fullyhumanized neutralizing antibodies to interleukin-8 (ABX-1L8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am.' Pathol (2002) 161:125–134.
   PubMed Web of Science ®Google Scholar
• YANG XD, CORVALAN JR, WANG P, ROY CM, DAVIS CG: Fully human anti-interleukin-8 monoclonal antibodies: potential therapeutics for the treatment of inflammatory disease states.' Leukoc. Biol. (1999) 66:401–410.
   PubMed Web of Science ®Google Scholar
• TORPHY TJ, LI L, GRISWOLD DE: Monoclonal antibodies as a strategy for pulmonary diseases. Carr. Opin. Pharmacol (2001) 1:265–271.
   PubMedGoogle Scholar
• FUJI WARA K, MATSUKAWA A, OHKAWARA S, TAKAGI K, YOSHINAGA M: Functional distinction between CXC chemokines, interleukin-8 (IL-8), and growth related oncogene (GRO)a in neutrophil infiltration. Lab. Invest. (2002) 82:15–23.
   PubMed Web of Science ®Google Scholar
• MUKAIDA N, MATSUMOTO T, YOKOI K et al.: Inhibition of neutrophil-mediated acute inflammatory injury by an antibody against interleukin-8 (IL-8). Intlainin. Res. (1998) 47\(Suppl. 3):s151–s157.
   Google Scholar
• HAY DW, SARAU HM: Interleuldn-8 receptor antagonists in pulmonary diseases. Cuir. Opin. Phannacol (2001) 1:242–247.
   PubMedGoogle Scholar
• AUTEN RL, RICHARDSON RM, WHITE JR, MASON SN, VOZZELLI MA, WHORTON MH: Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. Phannacol Exp. Thec (2001) 299:90–95.
   PubMed Web of Science ®Google Scholar
• GLYNN PC, HENNEY E, HALL IP: The selective CXCR2 antagonist 5B272844 blocks interleukin-8 and growth-related oncogene-alpha-mediated inhibition of spontaneous neutrophil apoptosis. Palm. Pharinacol Ther. (2002) 15:103–110.
   PubMed Web of Science ®Google Scholar
• LI F, ZHANG X, MIZZI C, GORDON JR: CXCL8((3-73))K11R/ G31P antagonizes the neutrophil chemoattractants present in pasteurellosis and mastitis lesions and abrogates neutrophil influx into intradermal endotoxin challenge sites in vivo. Vet. fininunol fininunopathol (2002) 90:65–77.
   PubMed Web of Science ®Google Scholar
• HEPBURN TW, HART TK, HORTON VL et al.: Pharmacokinetics and tissue distribution of SB-251353, a novel human CXC chemokine, after intravenous administration to mice. Pharinacol Exp. Thec (2001) 298:886–893.
   PubMed Web of Science ®Google Scholar
• BALY DL, HORUK R, YANSURA DG et al.: A His19 to Ala mutant of melanoma growth-stimulating activity is a partial antagonist of the CXCR2 receptor. fininunol (1998) 161:4944–4949.
   Google Scholar
• JONES SA, DEWALD B, CLARK-LEWIS I, BAGGIOLINI M: Chemokine antagonists that discriminate between interleukin-8 receptors: selective blockers of CXCR2.J Biol. Chem. (1997) 272:16166–16169.
   PubMed Web of Science ®Google Scholar
• CUTSHALL NS, KUCERA KA, URSINO R, LATHAM J, IHLE NC: Nicotinanilides as inhibitors of neutrophil chemotaxis. Bioorg. Med. Chem. Lett. (2002) 12:1517–1520.
   PubMed Web of Science ®Google Scholar
• CUTSHALL NS, URSINO R, KUCERA KA, LATHAM J, IHLE NC: Nicotinamide N-oxides as CXCR2 antagonists. Bioorg. Med. Chem. Lett. (2001) 11:1951–1954.
   PubMed Web of Science ®Google Scholar
• PODOLIN PL, BOLOGNESE BJ, FOLEY JJ et al.: A potent and selective nonpeptide antagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. Immunol (2002) 169:6435–6444.
   Web of Science ®Google Scholar
• FUJISAWA N, SAKAO Y, HAYASHI S, HADDEN WA 3rd, HARMON CL, MILLER EJ: a-Chemokine growth factors for adenocarcinomas; a synthetic peptide inhibitor for a-chemokines inhibits the growth of adenocarcinoma cell lines. Cancer Res. Clin. Oncol (2000) 126:19–26.
   PubMed Web of Science ®Google Scholar
• FUJISAWA N, HAYASHI S, MILLER EJ: A synthetic peptide inhibitor for a-chemokines inhibits the tumour growth and pulmonary metastasis of human melanoma cells in nude mice. Melanoma Res. (1999) 9:105–114.
   PubMed Web of Science ®Google Scholar
• MAUS U, VON GROTE K, KUZIEL WA et al.: The role of CC chemokine receptor 2 in alveolar monocyte and neutrophil immigration in intact mice. Am. I Respic Grit. Care Med. (2002) 166:268–273.
   PubMed Web of Science ®Google Scholar
• MICHALEC L, CHOUDHURY BK, POSTLETHWAIT E et al: CCL7 and CXCL10 orchestrate oxidative stress-induced neutrophilic lung inflammation. Immunol (2002) 168:846–852.
   Web of Science ®Google Scholar
• THOMAS MS, KUNKEL SL, LUKACS NW: Differential role of IFNy-inducible protein 10 kDa in a cockroach antigen-induced model of allergic airway hyperreactivity: systemic versus local effects. Immunol (2002) 169:7045–7053.
   Web of Science ®Google Scholar
• SALOMON I, NETZER N, WILDBAUM G, SCHIF-ZUCK S, MAOR G, KARIN N: Targeting the function of IFNy-inducible protein 10 suppresses ongoing adjuvant arthritis. Immunol (2002) 169:2685–2693.
   Web of Science ®Google Scholar
• CAPELLI A, DI STEFANO A, GNEMMI I et al: Increased MCP-1 and MIP-113 in bronchoalveolar lavage fluid of chronic bronchitics. Eur: Respic (1999) 14:160–165.
   PubMed Web of Science ®Google Scholar
• HAUTAMAKI RD, KOBAYASHI DK, SENIOR RIVI, SHAPIRO SD: Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science (1997) 277:2002–2004.
   PubMed Web of Science ®Google Scholar
• ••The first paper showing involvement ofCCL-2 in macrophage influx in lungs of mice upon smoke exposure, and the need for MMP-12 activation for tissue damage.
   Google Scholar
• MAUS U, HENNING S, WENSCHUH H, MAYER K, SEEGER W,LOHMEYER J: Role of endothelial MCP-1 in monocyte adhesion to inflamed human endothelium under physiological flow. Am. Physiol (2002) 283: H2584–H2591.
   PubMed Web of Science ®Google Scholar
• HORVATH C, WELT FG, NEDELMAN M, RAO P, ROGERS C: Targeting CCR2 or CD18 inhibits experimental in-stent restenosis in primates: inhibitory potential depends on type of injury and leukocytes targeted. Circ. Res. (2002) 90:484–494.
   Web of Science ®Google Scholar
• BECK CG, STUDER C, ZUBER JF, DEMANGE BJ, MANNING U, URFER R: The viral CC chemokine-binding protein vCCI inhibits monocyte chemoattractant protein-1 activity by masking its CCR2B-binding site. I Biol. Chem. (2001) 276:43270–43276.
   Web of Science ®Google Scholar
• RHODES A, SMITHERS N, CHAPMAN T, PARSONS S, REES S: The generation and characterisation of antagonist RNA aptamers to MCP-1. FEBS Lett. (2001) 506:85–90.
   PubMed Web of Science ®Google Scholar
• KUSCHERT GS, COULIN F, POWER CA et al.: Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry (1999) 38:12959–12968.
   PubMed Web of Science ®Google Scholar
• NI W, EGASHIRA K, KITAMOTO S et al.: New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation (2001) 103:2096–2101.
   PubMed Web of Science ®Google Scholar
• SCOZZAFAVA A, MASTROLORENZO A, SUPURAN CT: Non-peptidic chemokine receptors antagonists as emerging anti-HIV agents. Enzyme Inhib. Med. Chem. (2002) 17:69–76.
   PubMed Web of Science ®Google Scholar
• MIRZADEGAN T, DIEHL F, EBI B et al.: Identification of the binding site for a novel class of CCR2b chemokine receptor antagonists: binding to a common chemokine receptor motif within the helical bundle. Biol. Chem. (2000) 275:25562–25571.
   Web of Science ®Google Scholar
• •An extensive study on a class of inhibitors of CCR2b showing differential specificity towards the receptor. The report provides in vitro and in vivo data on their effectiveness.
   Google Scholar
• GONG J-H, CLARK-LEWIS I: Antagonists of monocyte chemoattractant protein 1 identiefied by modification of functionally critical NH2-terminal residues. Exp. Med. (1995) 181:631–640.
   PubMed Web of Science ®Google Scholar
• DAWSON J, MILTZ W, MIR AK, WIESSNER C: Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin. Ther. Targets (2003) 7:35–48.
   PubMed Web of Science ®Google Scholar
• •A recent and comprehensive overview of MCP-1 antagonists and their potential use for therapy in inflammatory diseases.
   Google Scholar
• WITHERINGTON J, BORDAS V, COOPER DG et al: Conformationally restricted indolopiperidine derivatives as potent CCR2B receptor antagonists. Bioorg. Med. Chem. Lett. (2001) 11:2177–2180.
   PubMed Web of Science ®Google Scholar
• ISHIBASHI M, EGASHIRA K, HIASA K et al.: Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension (2002) 40:687–693.
   PubMed Web of Science ®Google Scholar
• ZERNECKE A, WEBER KSC, ERWIG LP et al.: Combinatorial model of chemokine involvement in glomerular monocyte recruitment: role of CXC chemokine receptor 2 in infiltration during nephrotoxic nephritis. I Immunol (2001) 166:5755–5762.
   PubMed Web of Science ®Google Scholar
• DABBAGH K, XIAO Y, SMITH C et al.: Local blockade of allergic airway hyperreactivity and inflammation by the poxvirus-derived pan-CC-chemokine inhibitor vCCI. Immunol (2000) 165:3418–3422.
   Web of Science ®Google Scholar
• GAO P, ZHOU XY, YASHIRO-OHTANI Y et al.: The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Thl chemokine receptors CCR5 and CXCR3. j Leukoc. Biol. (2003) 73:273–280.
   PubMed Web of Science ®Google Scholar
• STRITZKI JM, XU S, WAGNER NE et al: SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection M vitro and in vivo. Proc. Natl. Acad. Sci. (2001) 98:12718–12723.
   PubMed Web of Science ®Google Scholar
• GUGLIELMOTTI A, D'ONOFRIO E, COLETTA I, AQUILINI L, MILANESE C, PINZA M: Amelioration of rat adjuvant arthritis by therapeutic treatment with bindarit, an inhibitor of MCP-1 and TNFa production. Inflamm. Res. (2002) 51:252–258.
   PubMed Web of Science ®Google Scholar
• RECKLESS J, TATALICK LM, GRAINGER DJ: The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-a accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo. Immunology (2001) 103:244–254.
   Google Scholar
• KRANENBURG AR, DE BOER WI, VAN KRIEKEN JHJM et al.: Enhanced expression of fibroblast growth factors and receptor FGFR-1 during vascular remodeling in chronic obstructive pulmonary disease. Am. I Respir. Cell MM. Biol. (2002) 27:517–525.
   Google Scholar
• •The first paper indicating an association between increased pulmonary expression of FGFs and vascular remodelling in COPD. Although descriptive, it provides clues for further research in this area.
   Google Scholar
• KUNICHIKA N, YUAN JXJ, KUNICHIKA H, MIYAHARA N, TANIMOTO M: Plasma levels of vascular endothelial growth factor are associated with severity of pulmonary hypertension due to chronic obstructive pulmonary disease. Chest (2002) 122 (Suppl.):143s.
   Google Scholar
• DE BOER WI, YILMAZ E, VAN SCHADEWIJK WAAM et al.: Expression of vascular endothelial growth factor in subjects with chronic obstructive pulmonary disease. Eur. Respir. (1997) 10\(Suppl. 25):457s.
   Google Scholar
• KASAHARA Y, TUDER PM, COOL CD, LYNCH DA, FL ORES SC, VOELKEL NF: Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am. J. Respir. Grit. Care Med. (2001) 163:737–744.
   PubMed Web of Science ®Google Scholar
• RICHARDSON PG, SCHLOSSMAN RL, WELLER E et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 100:3063–3067.
   PubMed Web of Science ®Google Scholar
• TUDER PM, ZHEN L, CHO CY et a]: Oxidative stress and apoptosis interact and cause emphysema due to VEGF receptor blockade. Am. J. Respir. Cell MM. Biol. (2003) (In press).
   Google Scholar
• •A mechanistic study showing that blocking VEGFR results in emphysema via oxidative stress and apoptosis of pneunctocytes in rats. Emphysema could be prevented by inhibiting oxidative stress or apoptosis.
   Google Scholar
• SALMON M, KILLIAN DJ, CARPENTER DC et al.: Activation of the p38 MAP kinase pathway following ozone exposure of mice: effect of SB 239063 a potent and selective inhibitor of p38 MAP kinase. Am. j Respir. Grit. Care Med. (2002) 165 (Suppl.):A84.
   Google Scholar
• UNDERWOOD DC, OSBORN RR, BOCHNOWICZ S et al.: SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol (2000) 279:L895–L902.
   PubMed Web of Science ®Google Scholar
• VAN DEN BLINK B, JUFFERMANS NP, TEN HOVE T et al.: p38 mitogen-activated protein kinase inhibition increases cytokine release by macrophages in vitro and during infection in vivo. J. Innnunol. (2001) 166:582–587.
   Google Scholar
• ZHANG C, BAUMGARTNER RA, YAMADA K, BEAVEN MA: Mitogen-activated protein (MAP) kinase regulates production of tumore necrosis factor-a and release of arachidonic acid in mast cells: indications of communication between p38 and p42 MAP kinases. I Biol. Chem. (1997) 272:13397–13402.
   Web of Science ®Google Scholar
• WOOD CC, YONG C-L, MADWED JB, GUPTA A: Safety, pharmacokinetics and pharmacodynamics of an oral p38 MAP kinase inhibitor (BIRB 796 BS), administered once daily for 7 days.' Allergy Immunol (2002) 109\(Supp1.):5321.
   Google Scholar
• GUPTA A, YONG C-L, MAD WELL JB, STAEHLE H, WOOD CC: Safety, pharmacokinetics, and pharmacodynamics of single doses of an oral p38 MAP kinase inhibitor (BIRB 796 BS) in healthy human males. A placebo-controlled, randomised study, double blinded at each dose level. Allergy Clin. Immunol (2002) 109(Suppl.):S67.
   Google Scholar
• BRAHN E, PROTTER AA, SCHOETZLER N et al.: Inhibition of collagen-induced arthritis with an inhibitor of p38 MAP kinase. Arthritis Rheum. (2002) 46\(Supp1.):S566.
   Google Scholar
• ZOU L, ATTUWAYBI B, KONE BC: Effects of NF-kappa B inhibition on mesenteric ischemia-reperfusion injury. Am. Physiol (2003) 284: G713–G721.
   PubMed Web of Science ®Google Scholar
• ASHIKAWA K, MAJUMDAR S, BANERJEE S, BHARTI AC, SHISHODIA S: Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. I Immunol (2002) 169:6490–6497.
   PubMed Web of Science ®Google Scholar
• ROSHAK AK, CALLAHAN JF, BLAKE SM: Small-molecule inhibitors of NF-kappaB for the treatment of inflammatory joint disease. Carr. Opin. Phannacol. (2002) 2:316–321.
   PubMed Web of Science ®Google Scholar
• TAKEHANA K, KONISHI A, 00NUKI A et al: APC0576, a novel inhibitor of NF-kappaB-dependent gene 1085 activation, prevents pro-inflammatory cytokine-induced chemokine production in human endothelial cells. Biochem. Biophys. Res. Commun. (2002) 293:945–952.
   Google Scholar
• VERNOOY JH, KOWKAYCAN M, JACOBS JA et al.: Local and systemic inflammation in patients with chronic obstructive pulmonary disease. Respir: Grit. Care Med. (2002) 166:1218–1224.
   PubMed Web of Science ®Google Scholar
• WEST R, MCNEILL A, RAW M: Smoking cessation guidelines for health professionals: an update. Thorax (2000) 55:987–999.
   PubMed Web of Science ®Google Scholar
• GALLAGHER J, FISHER C, SHERMAN B et al.: A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. Intensive Care Med. (2001) 27:1169–1178.
   PubMed Web of Science ®Google Scholar
• RUTGEERS P, LEMMENS L, VAN ASSCHE G, NOMAN M, BORGHINI-FUHRER I, GOEDKOOP R: Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment. Pharmacol. Ther. (2003) 172:185–192.
   Web of Science ®Google Scholar
• FUJITA M, HIRAYAMA T, IKEDA N: Design, synthesis and bioactivities of novel diarylthiophenes: inhibitors of tumor necrosis factor-alpha (TNF-alpha) production. Bioorg. Med. Chem. (2002) 10:3113–3122.
   PubMed Web of Science ®Google Scholar
• FUJITA M, SEKI T, INADA H, IKEDA N: Synthesis and bioactivities of novel 4,5,6, 7-tetrahydrothieno [2, 3-clpyridines as inhibitors of tumor necrosis factor-alpha (TNF-alpha) production. Bioorg. Med. Chem. Lett. (2002) 12:1607–1611.
   PubMed Web of Science ®Google Scholar
• MATSUI T, TAKAHASHI S, MATSUNAGA N et al.: Discovery of Novel Phosphonic Acid Derivatives as New Chemical Leads for Inhibitors of TNF-alpha production. Bioorg. Med. Chem. (2002) 10:3807–3815.
   PubMed Web of Science ®Google Scholar